WO2004111069A2 - New saponin compound, saponin solution containing the same a preparation method thereof, and pharmaceutical compositions, health foods and cosmetics containing the saponin as an active component - Google Patents
New saponin compound, saponin solution containing the same a preparation method thereof, and pharmaceutical compositions, health foods and cosmetics containing the saponin as an active component Download PDFInfo
- Publication number
- WO2004111069A2 WO2004111069A2 PCT/KR2004/001459 KR2004001459W WO2004111069A2 WO 2004111069 A2 WO2004111069 A2 WO 2004111069A2 KR 2004001459 W KR2004001459 W KR 2004001459W WO 2004111069 A2 WO2004111069 A2 WO 2004111069A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- saponin
- edible
- group
- ginseng
- composition liquid
- Prior art date
Links
- 229930182490 saponin Natural products 0.000 title claims abstract description 117
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims abstract description 114
- 150000007949 saponins Chemical class 0.000 title claims abstract description 80
- -1 saponin compound Chemical class 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 235000013402 health food Nutrition 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 84
- 239000007788 liquid Substances 0.000 claims abstract description 73
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 12
- 230000002500 effect on skin Effects 0.000 claims abstract description 12
- 230000006872 improvement Effects 0.000 claims abstract description 12
- 230000000144 pharmacologic effect Effects 0.000 claims abstract description 11
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 206010014568 Empyema Diseases 0.000 claims abstract description 7
- 206010019133 Hangover Diseases 0.000 claims abstract description 7
- 206010012504 Dermatophytosis Diseases 0.000 claims abstract description 6
- 241001460074 Microsporum distortum Species 0.000 claims abstract description 6
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 6
- 208000002474 Tinea Diseases 0.000 claims abstract description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 6
- 230000017531 blood circulation Effects 0.000 claims abstract description 6
- 230000002490 cerebral effect Effects 0.000 claims abstract description 6
- 230000001771 impaired effect Effects 0.000 claims abstract description 6
- 230000003908 liver function Effects 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims abstract description 5
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 5
- 240000004371 Panax ginseng Species 0.000 claims description 58
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 58
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 58
- 235000008434 ginseng Nutrition 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 13
- 150000007524 organic acids Chemical class 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 235000012907 honey Nutrition 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000007809 chemical reaction catalyst Substances 0.000 claims description 10
- 235000003599 food sweetener Nutrition 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- 239000003765 sweetening agent Substances 0.000 claims description 10
- 150000002016 disaccharides Chemical class 0.000 claims description 9
- 150000004676 glycans Chemical class 0.000 claims description 9
- 150000002772 monosaccharides Chemical class 0.000 claims description 9
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 150000002482 oligosaccharides Chemical class 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 8
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 8
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 8
- 241000196324 Embryophyta Species 0.000 claims description 8
- 240000004670 Glycyrrhiza echinata Species 0.000 claims description 8
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 8
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 8
- 244000082204 Phyllostachys viridis Species 0.000 claims description 8
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 8
- 239000011425 bamboo Chemical class 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229940010454 licorice Drugs 0.000 claims description 8
- 229910052709 silver Inorganic materials 0.000 claims description 8
- 239000004332 silver Substances 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 240000000425 Chaenomeles speciosa Species 0.000 claims description 6
- 235000005078 Chaenomeles speciosa Nutrition 0.000 claims description 6
- 240000007594 Oryza sativa Species 0.000 claims description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims description 6
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 claims description 6
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 6
- 235000009566 rice Nutrition 0.000 claims description 6
- 235000011511 Diospyros Nutrition 0.000 claims description 5
- 244000236655 Diospyros kaki Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 239000010931 gold Substances 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 235000021419 vinegar Nutrition 0.000 claims description 5
- 239000000052 vinegar Substances 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 241000209020 Cornus Species 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000007259 addition reaction Methods 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108020004707 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 239000008177 pharmaceutical agent Substances 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 239000011669 selenium Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 206010004542 Bezoar Diseases 0.000 claims description 3
- 208000034656 Contusions Diseases 0.000 claims description 3
- 241000402754 Erythranthe moschata Species 0.000 claims description 3
- 235000010804 Maranta arundinacea Nutrition 0.000 claims description 3
- 235000008599 Poria cocos Nutrition 0.000 claims description 3
- 244000197580 Poria cocos Species 0.000 claims description 3
- 244000145580 Thalia geniculata Species 0.000 claims description 3
- 235000012419 Thalia geniculata Nutrition 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 3
- 208000034526 bruise Diseases 0.000 claims description 3
- 210000004720 cerebrum Anatomy 0.000 claims description 3
- 210000003038 endothelium Anatomy 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 235000021422 persimmon vinegar Nutrition 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 2
- 240000006891 Artemisia vulgaris Species 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims description 2
- 241001609679 Cuscuta japonica Species 0.000 claims description 2
- 239000006000 Garlic extract Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 240000007890 Leonurus cardiaca Species 0.000 claims description 2
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 claims description 2
- 235000015468 Lycium chinense Nutrition 0.000 claims description 2
- 244000241872 Lycium chinense Species 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 241000241413 Propolis Species 0.000 claims description 2
- 241001618268 Rubus schizostylus Species 0.000 claims description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 2
- 240000006079 Schisandra chinensis Species 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000008157 edible vegetable oil Substances 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 235000020706 garlic extract Nutrition 0.000 claims description 2
- 229910052732 germanium Inorganic materials 0.000 claims description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910010272 inorganic material Inorganic materials 0.000 claims description 2
- 239000011147 inorganic material Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000011707 mineral Chemical class 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229940069949 propolis Drugs 0.000 claims description 2
- 229940109850 royal jelly Drugs 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 5
- 241000759833 Cornus officinalis Species 0.000 claims 1
- 239000003788 bath preparation Substances 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000011369 resultant mixture Substances 0.000 claims 1
- 235000017709 saponins Nutrition 0.000 description 98
- 208000024891 symptom Diseases 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 235000002789 Panax ginseng Nutrition 0.000 description 11
- 206010016256 fatigue Diseases 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000405911 Rehmannia glutinosa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 244000062793 Sorghum vulgare Species 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 235000015110 jellies Nutrition 0.000 description 4
- 239000008274 jelly Substances 0.000 description 4
- 235000019713 millet Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229940095714 cider vinegar Drugs 0.000 description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 2
- 206010071238 Binge Drinking Diseases 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- SWQINCWATANGKN-UHFFFAOYSA-N protopanaxadiol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC1C3(C)CCC(O)C(C)(C)C3CCC21C SWQINCWATANGKN-UHFFFAOYSA-N 0.000 description 2
- SHCBCKBYTHZQGZ-DLHMIPLTSA-N protopanaxatriol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2[C@@H](O)C[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C SHCBCKBYTHZQGZ-DLHMIPLTSA-N 0.000 description 2
- BBEUDPAEKGPXDG-UHFFFAOYSA-N protopanaxatriol Natural products CC(CCC=C(C)C)C1CCC2(C)C1C(O)CC3C4(C)CCC(O)C(C)(C)C4C(O)CC23C BBEUDPAEKGPXDG-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000010686 shark liver oil Substances 0.000 description 2
- 229940069764 shark liver oil Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- ZUWJMSFTDBLXRA-UHFFFAOYSA-N hexadecanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCC(O)=O ZUWJMSFTDBLXRA-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Definitions
- the present invention relates to a novel saponin compound, a saponin composition liquid containing the same, a preparation method thereof, and a pharmaceutical composition, functional food and cosmetic product containing the saponin compound or the saponin composition as an active ingredient.
- ginseng has been widely known as a representative nutritive tonic agent.
- ingredients and pharmacological activities of ginseng that have been known up to now include anti-aging, anti-arteriosclerosis, treatment of hyperlipidemia, treatment of hepatic insufficiency, improvement of liver function, protection from radiation injury, immune enhancement, improvement of cerebral function, antithrombotic, anti-stress, anti-diabetic, anti-hypertensive, anti-tumor effects, etc.
- research into such various pharmacological effects has focused on studies of ginseng extracts, specifically saponins that have been known to play a key role in exhibiting the efficacy of ginseng.
- Saponin components of ginseng are largely classified into three groups according to chemical structure: protopanaxadiol (PD); protopanaxatriol (PT); and oleanolic acid.
- Saponin existing on the plant system is a family of oleanane saponin, while ginseng saponin is dammarane-family triterpenoid saponin that is not isolated from the plant system.
- Ginseng saponins were found to be completely different from those found in other kinds of plants, thus they are called ginsenoside, meaning ginseng glycoside, so that they can be distinguished from other plant saponins.
- ginseng saponin components contained in ginseng in a large quantity include dammarane-family triterpenoid diols or triols.
- main components of ginseng saponin include three benzene rings, cyclopentane, sugar moieties (glycon) and more than 450 kinds of non-sugar moieties (aglycon).
- the inventor has reached findings that the novel saponin composition liquid has enhanced therapeutic effects of dermal eczema, tinea pedis, allergic dermatitis or atopic dermatitis, and treatment of other various diseases occurring to skin, eye, nose, mouth, tongue, pharynx, larynx, etc. as well as the same pharmacological efficacy as that of the conventional saponin composition liquid, finally completing the present invention.
- FIG. 1 is a spectral diagram showing High Performance Liquid Chromatograph (HPLC) analysis of a composition liquid according to the present invention
- FIG. 2 is a spectral diagram showing HLPC analysis of a composition prepared by Keumsan Ginseng Association of Korea.
- FIG. 3 a spectral diagram showing HLPC analysis of a composition of a Cheongkwanjang product that is Korean red ginseng prepared by KT&G Corporation.
- the present invention provides a novel saponin compound having the formula:
- radicals R 2 6 ⁇ R29, R'4, R' ⁇ and R'io represent hydrogen atom, or a glycon of monosaccharides, disaccharides, oligosaccharides or polysaccharides, a glycon of monosaccharides, disaccharides, oligosaccharides or polysaccharides may be optionally bonded to a carbon[C] on a double bond of the hexagonal ring or the pentagonal ring, and wherein at least one selected from the group consisting of the following groups is induced by an addition reaction into the radicals R 26 ⁇ R2 9 , R4, R f 9 and R' 10 or a carbon atom on a double bond of the hexagonal ring or the heptagonal ring: a group of edible organic acids containing 1 to 20 carboxyl groups; a group of flavonoids having a backbone containing three phenyl groups contained in edible propolis;
- novel saponin compound according to the present invention has a variety of chemical structures according to the position where the addition reaction occurs.
- novel saponin compound and a saponin composition liquid comprising the novel saponin compound are prepared in the following manner.
- the above formula can be simply explained based on the Onewholeness Theory, as proposed by the inventor of the present invention, the data of which is available upon request.
- Ginseng is immersed in a sweet drink made from rice or a residual liquid produced in the previous preparation process of the saponin composition liquid for 10 minutes to 1 hour, and aged in a closed vessel. That is, the ginseng or dried ginseng of either stem or leaf is aged at a temperature of 40 to 60 0 C for 7 to 21 days, and fresh ginseng is aged at a temperature of 20 to 50 0 C for 1 to 7 days. The aging may cause degeneration of alkaloid compounds on the epidermis of the ginseng. 2) Sugar addition step
- the pretreated ginseng was injected into an extraction reactor with a reflux device together with saccharides, edible organic acids, edible salts, reaction catalysts and water, or optionally with edible sweeteners.
- the reaction was maintained at 120 0 C, under atmospheric pressure for 20 hours or more, and the injected materials including ginseng is removed
- the preheated ginseng is used in an amount of 1 to 30 wt%, preferably 5 to 25 wt%, based on the total weight of water used.
- saccharide useful in the present invention examples include honey, monosaccharides, disaccharides, oligosaccharides, and polysaccharides.
- the saccharide is used in an amount of 1 to 20 wt%, preferably 1.5 to 15 wt%.
- polysaccharide examples include one selected from the group consisting of pulluran, amylose xyloglucans, amylopectin, dextran, cyclodextrin, mannans, hydroxyethyl dextrans, inulin, chitin, chitosans, and aqueous celluloses.
- edible salt useful in the present invention include a single substance or a mixture of two or more materials selected from the group consisting of bay salt, bamboo salt, mineral salt, and parched salt, and is used in an amount of 0.05 to 2 wt%, preferably 0.1 to 1 wt%.
- reaction catalyst useful in the present invention include a single substance or a mixture of two or more materials selected from the group consisting of platinum, gold, silver, zinc, copper, selenium and elvan, and is used in an amount of 0.05 to 2 wt%, preferably 0.1 to 1 wt%.
- Examples of the edible organic acid dried pharmaceutical agent useful in the present invention include a single substance or a mixture of two or more materials selected from the group consisting of formic acid, citric acid, succinic acid, maleic acid, acetic acid, alum, plum, Chinese quince, mugwort, motherwort, garlic extract, persimmon vinegar, and unhulled rice vinegar, and is used in an amount of 0.1 to 3 wt%, preferably 0.3 to 2 wt%.
- Examples of the edible sweetener useful in the present invention include a single substance or a mixture of two or more materials selected from the group consisting of honey, royal jelly, monosaccharide, disaccharides, such as oligosaccharides, polysaccharide, black sugar, jujube, licorice, raisin, dried persimmon, arrow root, Schisandra chinensis, rubus schizostylu, comus officinalis, lycium chinense, cuscuta japonica, Rehmaniae radix preparata, poria cocos, ox bezoar, musk, powdered cervi cornus, cervi pantotrichum comu, bear gall, pig gall, and edible proteins including mushrooms.
- the edible sweetener is used in an amount of 0.1 to 3 wt%, preferably 0.3 to 2 wt%.
- Pure compounds of the formula I can be isolated by subjecting the saponin compounds to general purification and separation techniques, such as chromatography or extraction using an organic solvent.
- the present invention provides a pharmaceutical composition and functional food containing the novel saponin compound of the formula I or a saponin composition liquid containing the saponin compound as an active ingredient.
- the pharmaceutical composition and functional food have various pharmacological effects including immune enhancement, vitality enhancement, improvement of liver function, withdrawal of hangover, promotion of protein generation, promotion of cerebral activities and improvement of attention, activated recuperation of health after surgical operation, and prevention or treatment of diabetes, impaired blood circulation, depression, dermal inflammatory disease, dermal eczema, dermatophytosis, allergic rhinitis, and empyema, and promoting generation of protein effective in treatment and prevention of a bruise, a burn, bleeding internal diseases, and regeneration of protein in the cerebrum, medullar, or endothelium/exothelium.
- the pharmaceutical composition and functional food have enhanced therapeutic effects of dermal eczema, tinea pedis, allergic dermatitis or atopic dermatitis, and treatment of other various diseases occurring to skin, eye, nose, mouth, tongue, pharynx, larynx, etc.
- the novel saponin compound is preferably contained in an amount of not less than 0.01 wt%.
- the pharmaceutical composition can be formulated in a variety of dosage forms, including oral administration, parenteral administration and topical administration.
- the pharmaceutical composition can be formulated, in combination with a pharmaceutically acceptable carrier, into oral dosage forms including granules, capsules, solutions, or suspensions, injectables, suspensions, topical preparations including ointments, creams or solutions, suppositories, and other various dosage forms.
- the carrier used in combination with the composition according to the present invention is a pharmaceutically acceptable carrier.
- examples of the carrier include binders, humectants, disintegrating agents, adjuvants, solubilizers, dispersants, stabilizers, suspensions, coloring agents, or flavoring agents.
- examples of the carrier include preservatives, pain relieving agents, solubilizers, or stabilizers.
- examples of the carrier include basic matrixes, adjuvants, lubricants, or preservatives.
- the thus prepared pharmaceutical formulations can be administered either orally or parenterally. Also, in order to prevent the drug from being dissolved in gastric acid during oral administration, an obstipatia can also be used.
- solid formulations for oral administration e.g., granules
- enteric-coated dosage form can be formulated in the enteric-coated dosage form.
- Doses of the compositions according to the present invention may vary according to the formulation, and the desirable dose to be administered may be appropriately selected according to the absorption, inactivation rate and excretion speed of active ingredients, the age, sex and severity of a subject.
- the saponin compound is preferably administered at a dose of 10 ⁇ 30 mg 1 ⁇ 3 times per day
- the saponin composition liquid is preferably administered at a dose of 20 ⁇ 30 cc 1 ⁇ 3 times per day.
- the present invention provides a cosmetic product comprising the novel saponin compound or the saponin composition liquid as an active ingredient.
- the cosmetic product contains the novel saponin composition liquid as the active ingredient, the novel saponin composition liquid is preferably contained in an amount of 30 - 90 wt% based on the total weight of the composition.
- the cosmetic product of the present invention may include 5-25 wt% of edible ethyl alcohol, 0.5 ⁇ 5 wt% of a herbal extract, and 0.1-50 wt%, preferably 0.5-35 wt%, of a general additive.
- the herbal extract is one or more edible vegetable extracts selected from the group consisting of cucumber, sponge goard, aloe and cordyceps extracts, and one or more additives selected from the group consisting of bush mushroom, agaric mushroom, bus mushroom, topspin mushroom, Reishi mushroom, oak mushroom, cordyceps sinensis, Angelicae gigantis radix, rehmannia glutinosa, white poria cocos, ox bezoar, musk, cervi cornus powder, cervi pantotrichum cornu, bear gall, and pig gall.
- the general additive is one or more selected from the group consisting of one or more honey wax, paraffin oil, shark liver oil, caviar, pectins.
- the cosmetic product according to the present invention can be formulated in the form of skin lotion, moisturizing lotion, or creams.
- the cosmetic product according to the present invention may be formulated in the form of a skin-cleansing agent, a hair care agent, shower and baths preparations, make-up cosmetics and skin care cosmetics.
- Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 60 minutes, and aging the resultant ginseng at a temperature of about 25 0 C for one day.
- the reaction catalyst was injected into a lower portion of the extraction reactor, the saccharide, the bamboo salt and the organic acid were dissolved in water and the ginseng and the dried pharmaceutical agents were injected into an upper portion of the extraction reactor, causing a reaction for approximately 40 hours at approximately 120 0 C under atmospheric pressure for extraction. Then, solid matters such as ginseng were filtered for removal and evaporated under reduced pressure for removal of water, yielding not greater than 3000 g of the extract, thereby obtaining a saponin composition liquid containing saponin compounds of the formula I.
- Preparation Example 2 Saponin composition liquid Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 30 minutes and aging the resultant ginseng at a temperature of about 30 0 C for two days.
- Preparation Example 3 Saponin composition liquid Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 20 minutes, and aging the resultant ginseng at a temperature of about 27 0 C for 5 days.
- Preparation Example 4 saponin composition liquid Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 40 minutes, and aging the resultant ginseng at a temperature of about 25 0 C for 10 days.
- 300 g of the pretreated ginseng 100 g of a combination containing 80 g of honey, 10 g of glucose and 10 g of millet jelly, 40 g of an edible sweetener consisting of 20 g of jujube, 10 g of boiled rehmannia glutinosa, 5 g of licorice and 5 g of dried persimmon, 20 g of an edible organic acid consisting of 19 g of plum and 1 g of citric acid, 1.5 g of bamboo salt, a reaction catalyst consisting of 19 g of elvan and 1 g of platinum sand, and 3000 g of water, were separately injected into an extraction reactor provided with a reflux device.
- Preparation Example 5 Saponin composition liquid Ginseng was first pretreated by immersing the same in a residual liquid produced in the previous preparation process of a saponin composition liquid for 15 minutes, and aging the resultant ginseng at a temperature of about 32 ° C for one day.
- the pretreated ginseng 150 g of a combination containing 100 g of honey and 50 g of millet jelly, 30 g of an edible sweetener consisting of 25 g of jujube, 2 g of licorice and 3 g of boiled rehmannia glutinosa, 5 g of licorice and 5 g of dried persimmon, 40 g of an edible organic acid consisting of 20 g of plum, 10 g of Chinese quince, 5 g of cider vinegar and 5 g of unhulled rice vinegar, 2 g of bamboo salt, a reaction catalyst consisting of 5 g of pellet-type silver and 25 g of elvan, and 3000 g of water, were separately injected into an extraction reactor provided with a reflux device.
- an edible sweetener consisting of 25 g of jujube, 2 g of licorice and 3 g of boiled rehmannia glutinosa, 5 g of licorice and 5 g of dried
- a skin lotion having the following composition was prepared using the saponin composition liquid prepared in Preparation Example 1 : Saponin composition liquid 60 wt%
- a moisturizing lotion having the following composition was prepared using the saponin composition liquid prepared in Preparation Example 1 : Saponin composition liquid 70 wt%
- the peaks detected from the compound according to the present invention were greater than or equal to 9 mV.
- the peak exhibited by the compound 2 is not detectable from the conventional red ginseng and a gentle peak of 2.5 mV was observed.
- the peak exhibited by the compound according to the present invention has a gentle profile around 100 minutes, which is completely new compared to the conventional case, suggesting that the new peak is exhibited by the novel compound prepared in the present invention.
- Tables 1 and 2 show the results illustrated in FIGS. 1 and 2.
- the contents of the saponin components according to the present invention are measured using data shown in Table 1 , and the measurement results are shown in Table 3.
- Table 1 The contents of the saponin components according to the present invention are measured using data shown in Table 1 , and the measurement results are shown in Table 3.
- Clinical test example 1 Age: 55 (Male) Symptoms: Hand eczema, dermatophytosis
- Preparation Example 1 was applied to a subject having eczema sites on hand and foot three times daily over a period of 3 to 10 days. The result showed that the skin became softened and bright-complexioned without inducing any symptoms of the eczema.
- Preparation Example 3 was administered twice over a period of 90 days. Thereafter, vitality was recovered and chronic fatigue was cured while the attention was improved. Also, unusually dark and rough skin was whitened and softened.
- Preparation Example 4 was diluted in 1 cup of water and administered once or twice daily over a period of 100 days. After administration of the diluted saponin composition liquid, the state of depression was overcome, the vitality was recovered and the fatigue was cured. The dark-yellow, coarse skin became whitened, softened and bright-complexioned.
- Symptoms Pneumonic symptoms, weakened immunity Result: 5 cc of the saponin composition liquid prepared in Preparation Example 5 was administered twice daily over a period of 2 weeks. After administration of the saponin composition liquid, the vitality was recovered and the fatigue was cured. The dark-yellow, coarse skin became whitened and softened.
- Symptoms Common cold and complications due to weakened immunity Result: After administration of 20 cc of the saponin composition liquid prepared in Preparation Example 2 once daily over a period of 60 days, the immunity was fortified and the vitality was recovered, so that cold complications were withdrawn from the subject without suffering from the cold.
- Symptoms Symptoms occurring during the period of convalescence after gastrotomy
- Clinical test example 10 Age: 50 (Female) Symptoms: Crural bloat due to impaired blood circulation and diabetic symptoms
- Symptoms Diabetes, cold and bacterial complications Result: After administration of 25 cc of the saponin composition liquid prepared in Preparation Example 2 twice daily over a period of 40 days, the immunity for bacterial diseases was fortified and the vitality was recovered, so that various complications were withdrawn. Also, fortified metabolism of carbohydrates noticeably lowered the glucose level.
- Skin lotion and moisturizing lotion prepared in Preparation Examples 6 and 7 were continuously applied to seven 22 to 42 old women who cannot use general cosmetic products due to their hypersensitive skin three times daily over a period of a week. As a result, no hypersensitive response and skin irritation occurred.
- the pharmaceutical composition and functional food comprising a saponin compound or a saponin composition liquid containing the same as an active ingredient has various pharmacological effects, including immune enhancement, vitality enhancement, improvement of liver function, withdrawal of hangover, promotion of protein generation, promotion of cerebral activities and improvement of attention, activated recuperation of health after surgical operation, and prevention or treatment of diabetes, impaired blood circulation, depression, dermal inflammatory disease, dermal eczema, dermatophytosis, allergic rhinitis, empyema, and so on.
- the cosmetic product comprising the saponin compound or a saponin composition liquid containing the saponin compound can also be suitably applied to the person who has sensitive skin.
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0039622 | 2003-06-19 | ||
KR20030039622 | 2003-06-19 | ||
KR20030053378 | 2003-08-01 | ||
KR10-2003-0053378 | 2003-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004111069A2 true WO2004111069A2 (en) | 2004-12-23 |
Family
ID=33554578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2004/001459 WO2004111069A2 (en) | 2003-06-19 | 2004-06-18 | New saponin compound, saponin solution containing the same a preparation method thereof, and pharmaceutical compositions, health foods and cosmetics containing the saponin as an active component |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100746799B1 (en) |
WO (1) | WO2004111069A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006223140A (en) * | 2005-02-16 | 2006-08-31 | Kiyoshi Sato | Dietary supplement |
GB2455585A (en) * | 2008-01-16 | 2009-06-17 | Ali Reza Rezai-Fard | Composition for treating a skin disorder |
US7981308B2 (en) | 2007-12-31 | 2011-07-19 | Robert Bosch Gmbh | Method of etching a device using a hard mask and etch stop layer |
CN103613680A (en) * | 2013-12-05 | 2014-03-05 | 三峡大学 | Alcohol-precipitated panax japonicus polysaccharide, preparation method and application thereof |
CN104383028A (en) * | 2014-10-30 | 2015-03-04 | 洛阳蓝斯利科技有限公司 | Method for preparing liquorice foot bath powder |
CN114957495A (en) * | 2022-01-04 | 2022-08-30 | 北华大学 | Schisandra chinensis plant polysaccharide and preparation method and application thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101106499B1 (en) * | 2009-03-24 | 2012-01-20 | 장흥군 | Food composition with hepatoprotective effect containing the peduncle extracts of Hovenia dulcis Thunb |
KR101155967B1 (en) * | 2009-09-11 | 2012-06-18 | 김달수 | A health food composition for prevention and treatment of allergic rhinitis containing Germanium, elvan and red ginseng Extracts |
KR101947595B1 (en) * | 2011-09-30 | 2019-02-15 | (주)아모레퍼시픽 | Surfactant containing saponin extracted from the root of Camellia sinensis and Liquid cleansing composition comprising the same |
KR101380556B1 (en) * | 2012-04-26 | 2014-04-01 | 합자회사 에스에이치해양수산개발 | Soap composition comprising salt having saponin from sea slug and preparation method thereof |
KR101998562B1 (en) * | 2016-10-06 | 2019-07-10 | 농업회사법인 월파 주식회사 | How to make red ginseng sikhye |
KR102247551B1 (en) * | 2020-12-31 | 2021-05-03 | 주식회사 네이처프롬 | A cream that can relieve swelling by using ginseng water and a method of manufacturing it |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR930005989B1 (en) * | 1991-01-22 | 1993-07-01 | 주식회사 대웅제약 | Preparation of |3-0-(2',3',4',6'-tetra-0-acetyl-beta-d-glucopyranosyl)-20(s)-protopanaxadiol¨ |
KR0169536B1 (en) * | 1996-02-27 | 1999-01-15 | 손경식 | Novel ginseng saponins, process for preparation thereof and anti-tumor agents containing the same as an active ingredient |
-
2004
- 2004-06-18 WO PCT/KR2004/001459 patent/WO2004111069A2/en active Application Filing
- 2004-06-18 KR KR1020057024035A patent/KR100746799B1/en not_active IP Right Cessation
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006223140A (en) * | 2005-02-16 | 2006-08-31 | Kiyoshi Sato | Dietary supplement |
US7981308B2 (en) | 2007-12-31 | 2011-07-19 | Robert Bosch Gmbh | Method of etching a device using a hard mask and etch stop layer |
US8232143B2 (en) | 2007-12-31 | 2012-07-31 | Robert Bosch Gmbh | Device formed using a hard mask and etch stop layer |
GB2455585A (en) * | 2008-01-16 | 2009-06-17 | Ali Reza Rezai-Fard | Composition for treating a skin disorder |
GB2455585B (en) * | 2008-01-16 | 2010-07-28 | Ali Reza Rezai-Fard | Capsicum seeds for the treatment of eczema and dermatitis |
CN103613680A (en) * | 2013-12-05 | 2014-03-05 | 三峡大学 | Alcohol-precipitated panax japonicus polysaccharide, preparation method and application thereof |
CN103613680B (en) * | 2013-12-05 | 2016-06-01 | 三峡大学 | Alcohol-precipitated panax japonicus polysaccharide, preparation method and application thereof |
CN104383028A (en) * | 2014-10-30 | 2015-03-04 | 洛阳蓝斯利科技有限公司 | Method for preparing liquorice foot bath powder |
CN114957495A (en) * | 2022-01-04 | 2022-08-30 | 北华大学 | Schisandra chinensis plant polysaccharide and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100746799B1 (en) | 2007-08-23 |
KR20060038396A (en) | 2006-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100534474C (en) | Medicine composition for enhancing immunity, and its preparation method and use | |
DE3328262A1 (en) | PREPARATION OF MEDICINES FOR IMPROVING CANCER SYMPTOMS | |
KR20100105346A (en) | Composition for immune enhancement comprising the extract of young antler, cornus officinalis, ligusticum acutilobum, chinese matrimony vine, yam, aurantii nobilis pericarpium, gastrodia elata blume, agastache rugosa, cinnamomum loureirii, ginseng steamed red and schizandra chinensis, as an active ingredient | |
WO2004111069A2 (en) | New saponin compound, saponin solution containing the same a preparation method thereof, and pharmaceutical compositions, health foods and cosmetics containing the saponin as an active component | |
CN103168883A (en) | Pathogenic microorganism preventing antiviral tea beverage granules capable of boosting immunity and preparation method thereof | |
KR100635025B1 (en) | A ginseng preparation using vinegar and process for thereof | |
CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
EP4205558A1 (en) | Health functional food, comprising siberian chrysanthemum extract, for pain relief or antioxidation | |
CN101744986B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
CN1814214A (en) | Chinese medicine composition for treating body thin and delicate coustitution, and preparing method | |
KR20030080296A (en) | Composition containing saponin fraction and derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
CN101744991B (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
CN107595870B (en) | Brain-strengthening and nerve-soothing pharmaceutical composition, pharmaceutical preparation, application and preparation method | |
KR101416669B1 (en) | Ginseng prosapogenin high concentration containing ginseng berry preparation using sonication and process for thereof | |
CN101744997B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
CN101745014B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
CN101745012B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
CN101745017B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
CN101744996B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
KR20010009653A (en) | Composition for treating sexual dysfunction | |
JP2014155489A (en) | Composition for preventing and treating diabetes, containing smilax china l. leaves extract | |
KR101671571B1 (en) | A ginseng seed composition having inhibitory effect of glucose absorption and preparing method thereof | |
CN113521186B (en) | Hypoglycemic drug and preparation method and application thereof | |
CN101745000B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
CN101745006B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020057024035 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057024035 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |